• Explore /
  • Videos & Slides
  • / Nivolumab and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis.

Nivolumab and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis.

Abstract Video & Slides Poster

Presenter

Peter Cole

Peter D. Cole, MD

Rutger’s Cancer Institute of New Jersey

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Videos & Slides Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Hodgkin Lymphoma

Clinical Trial Registration Number

NCT02927769

Citation

J Clin Oncol 38: 2020 (suppl; abstr 8013)

DOI

10.1200/JCO.2020.38.15_suppl.8013

Abstract #

8013

Poster Bd #

346

Abstract Disclosures

Similar Videos & Slides

Speaker: Paul David Harker-Murray, MD, PhD

Speaker: Charlotte Burton Wagner, PharmD, BCOP

Speaker: John Kuruvilla, MD

Speaker: Rayne H. Rouce, MD